Literature DB >> 26900224

Antiretroviral therapy: Shifting sands.

V K Sashindran1, Rajeev Chauhan2.   

Abstract

HIV/AIDS has been an extremely difficult pandemic to control. However, with the advent of antiretroviral therapy (ART), HIV has now been transformed into a chronic illness in patients who have continued treatment access and excellent long-term adherence. Existing indications for ART initiation in asymptomatic patients were based on CD4 levels; however, recent evidence has broken the shackles of CD4 levels. Early initiation of ART in HIV patients irrespective of CD4 counts can have profound positive impact on morbidity and mortality. Early initiation of ART has been found not only beneficial for patients but also to community as it reduces the risk of transmission. There have been few financial concerns about providing ART to all HIV-positive people but various studies have proven that early initiation of ART not only proves to be cost-effective but also contributes to economic and social growth of community. A novel multidisciplinary approach with early initiation and availability of ART at its heart can turn the tide in our favor in future. Effective preexposure prophylaxis and postexposure prophylaxis can also lower transmission risk of HIV in community. New understanding of HIV pathogenesis is opening new vistas to cure and prevention. Various promising candidate vaccines and drugs are undergoing aggressive clinical trials, raising optimism for an ever-elusive cure for HIV. This review describes various facets of tectonic shift in management of HIV.

Entities:  

Keywords:  Antiretroviral therapy (ART); Challenges; Guidelines; Human immunodeficiency virus (HIV)

Year:  2016        PMID: 26900224      PMCID: PMC4723694          DOI: 10.1016/j.mjafi.2015.12.002

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  33 in total

1.  Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Authors:  Dale J Kempf; Martin S King; Barry Bernstein; Paul Cernohous; Eric Bauer; Jennifer Moseley; Kai Gu; Ann Hsu; Scott Brun; Eugene Sun
Journal:  J Infect Dis       Date:  2003-12-31       Impact factor: 5.226

2.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

3.  Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Authors:  Edwin Dejesus; Benjamin Young; Javier O Morales-Ramirez; Louis Sloan; Douglas J Ward; John F Flaherty; Ramin Ebrahimi; Jen-Fue Maa; Karen Reilly; Janet Ecker; Damian McColl; Daniel Seekins; Awny Farajallah
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

4.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

5.  Didehydro-Cortistatin A: a new player in HIV-therapy?

Authors:  Guillaume Mousseau; Susana T Valente
Journal:  Expert Rev Anti Infect Ther       Date:  2015-12-11       Impact factor: 5.091

6.  Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.

Authors:  Matthew P Fox; Gilles Van Cutsem; Janet Giddy; Mhairi Maskew; Olivia Keiser; Hans Prozesky; Robin Wood; Miguel A Hernán; Jonathan A C Sterne; Matthias Egger; Andrew Boulle
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

7.  Economic returns to investment in AIDS treatment in low and middle income countries.

Authors:  Stephen Resch; Eline Korenromp; John Stover; Matthew Blakley; Carleigh Krubiner; Kira Thorien; Robert Hecht; Rifat Atun
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

8.  Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia.

Authors:  Christina Konstantopoulos; Heather Ribaudo; Kathleen Ragland; David R Bangsberg; Jonathan Z Li
Journal:  Open Forum Infect Dis       Date:  2015-01-14       Impact factor: 3.835

Review 9.  Long-acting antiviral agents for HIV treatment.

Authors:  David A Margolis; Marta Boffito
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

10.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Authors:  Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister
Journal:  Lancet Infect Dis       Date:  2015-11-02       Impact factor: 25.071

View more
  1 in total

1.  Perceptions of alcohol use in the context of HIV treatment: a qualitative study.

Authors:  Munyaradzi Madhombiro; Bazondlile Marimbe-Dube; Michelle Dube; Malinda Kaiyo-Utete; Angeline Paradzai; Dixon Chibanda; Simbarashe Rusakaniko; Asj van der Watt; Soraya Seedat
Journal:  HIV AIDS (Auckl)       Date:  2018-04-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.